Gilead Acquires Tubulis, Boosting Oncology Pipeline

Andera Partners announced that Gilead Sciences has agreed to acquire Tubulis GmbH, a German biotechnology company. This acquisition aims to enhance Gilead's oncology pipeline by adding potentially superior antibody-drug conjugates (ADCs) and a next-generation platform. Tubulis, known for its conjugation technology, offers assets like TUB-040 and TUB-030, both targeting various solid tumors.

The agreement includes a $3.15 billion cash payment upfront, alongside potential milestone payments of up to $1.85 billion. This acquisition is expected to close in Q2 2026, pending regulatory approvals. Tubulis will operate as a research hub within Gilead post-acquisition, focusing on ADC innovation.

Gilead plans to fund this transaction using cash and senior unsecured notes. Andera Partners praised Tubulis's accomplishments and role within the acquisition, highlighting its transformative impact on the field of ADCs.